APR 20, 2022 3:00 AM PDT

"Saturating" the Liver with Chemotherapy to Treat Cancer

WRITTEN BY: Katie Kokolus

Uveal melanoma is a rare type of cancer that grows in the melanin, the dark-colored pigment of the eye. About half of patients with uveal melanoma experience metastasis characterized by the spread of cancer cells to distant parts of the body. The liver is the most commonly inflicted secondary organ in metastatic uveal melanoma (mUM). Sadly, 75 - 90% of mUM cases prove fatal.  

Currently, there is no standard-of-care treatment for mUM and developing an efficacious treatment modality remains a research focus. Immunotherapies are used in some cases, but they garner less than a 20% response rate in treating mUM. Percutaneous hepatic perfusion of melphalan (M-PHP) has emerged as a promising investigative technique for treating liver metastasis. M-PHP has many benefits, including that it is a minimally invasive procedure that typically results in minimal adverse effects. Initial trials suggest M-PHP could significantly benefit patients with liver metastases.  

M-PHP administers chemotherapy directly to the liver to treat liver cancer or liver metastases.  Because the liver is soaked, or “saturated”, with high-dose chemotherapy, this technique is considered “chemosaturation” therapy. 

Doctors insert a thin tube, known as a cannula, into the hepatic artery, the blood vessel that delivers oxygenated blood to the liver and pancreas.  Melphalan, a chemotherapy, is then delivered to the liver via the cannula. To limit damage to healthy tissue throughout the body, doctors will perform a venobenous bypass procedure. The chemotherapy-infused blood exiting the liver is collected, the harmful chemotherapeutic metabolites are filtered out, and the blood is returned to the patient, re-entering normal circulation.  

To expand on some of the clinical data on M-PHP, a group of researchers from the United Kingdom initiated a retrospective study analyzing the outcome of a large cohort of patients.  The study results, recently published in Melanoma Research, demonstrate safety and efficacy for mUM patients with liver metastasis treated with chemosaturation therapy. 

The researchers utilized data from 81 mUM patients who received M-PHP.  On average, patients underwent three rounds of treatment.  The authors reported the disease control rate at 88.9% and the overall response rate at 60.5%.  At the time of analysis, the median follow-up time was about 13 months.  The study found that the median overall progression-free was 8.4 months, and the median overall survival was almost 15 months. 

The authors acknowledged some limitations of their study, including the lack of a control or alternatively treated arm. Further, the authors suggest that combining chemosaturation with immunotherapy could further enhance the benefit to mUM patients. In particular, they indicate IDO and TIGIT as potential targets for a combinatorial immunotherapy approach.    

 

Sources: Oncol Ther, Opthamology, Oncoimmunology, Hepatoma Res, Ann Surg Oncol, Mel Res, Transplantation Proc, Cancer Cell

About the Author
PhD
PhD in Tumor Immunology. I am interested in developing novel strategies to improve the efficacy of immunotherapies used to extend cancer survivorship.
You May Also Like
APR 26, 2022
Immunology
Unraveling the Mystery of an Immune Cell Checkpoint
APR 26, 2022
Unraveling the Mystery of an Immune Cell Checkpoint
The immune system can get tired when it has to fight against a chronic infection or a disease like cancer. Exhausted T c ...
MAY 01, 2022
Health & Medicine
Predicting Radiotherapy Resistance in Brain Metastases
MAY 01, 2022
Predicting Radiotherapy Resistance in Brain Metastases
Radiotherapy for brain metastasis can later cause neurocognitive decline. Sometimes this is a tradeoff when fightin ...
JUL 19, 2022
Clinical & Molecular DX
As Rates of Thyroid Cancer Continue to Increase, Researchers Question Why
JUL 19, 2022
As Rates of Thyroid Cancer Continue to Increase, Researchers Question Why
Beginning in the early 1990’s, rates of thyroid cancer began to drastically increase. Though this trend has contin ...
JUL 18, 2022
Cancer
Melanocytic Nevi and their Association with Melanoma
JUL 18, 2022
Melanocytic Nevi and their Association with Melanoma
Melanocytes describe a specialized type of cell that generates a substance called melanin, a pigment responsible for ski ...
JUL 28, 2022
Cancer
Potential Marker for Prostate Cancer Prognosis Identified
JUL 28, 2022
Potential Marker for Prostate Cancer Prognosis Identified
Cytokines, proteins that affect the immune system, can elicit their effects in either a beneficial or an inhibitory capa ...
AUG 01, 2022
Cancer
Cannabis Helps Cancer Patients Combat Nausea and Vomiting
AUG 01, 2022
Cannabis Helps Cancer Patients Combat Nausea and Vomiting
A growing number of states have legalized marijuana for medical and/or recreational purposes.  Cannabis is a plant ...
Loading Comments...